Taken together, these results indicate that CCL19 is capable of promoting the Ag-responsive CCR7+ lymphocyte proliferations and differentiations in patients that may subsequently develop into functional cytotoxic T (CD8+ T) cells, which suggests that CCL19 may help HBV clearance in AHB, HCC, and CHB individuals. This evidence concerns the gene CD8A and hepatocellular carcinoma.